Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30068682HIVENSG00000120899.18protein_codingPTK2BNoNo2185Q14289
TVIS20010950HPVENSG00000120899.18protein_codingPTK2BNoNo2185Q14289
TVIS20035837HPVENSG00000120899.18protein_codingPTK2BNoNo2185Q14289
TVIS20062749HPVENSG00000120899.18protein_codingPTK2BNoNo2185Q14289
TVIS20068063HPVENSG00000120899.18protein_codingPTK2BNoNo2185Q14289
TVIS20062536HPVENSG00000120899.18protein_codingPTK2BNoNo2185Q14289
TVIS44008179HTLV-1ENSG00000120899.18protein_codingPTK2BNoNo2185Q14289
TVIS44004500HTLV-1ENSG00000120899.18protein_codingPTK2BNoNo2185Q14289
TVIS44014724HTLV-1ENSG00000120899.18protein_codingPTK2BNoNo2185Q14289
TVIS44019961HTLV-1ENSG00000120899.18protein_codingPTK2BNoNo2185Q14289
TCGA Plot Options
Drug Information
GenePTK2B
DrugBank IDDB12010
Drug NameFostamatinib
Target IDBE0000871
UniProt IDQ14289
Regulation Typeinhibitor
PubMed IDs26516587
CitationsRolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4.
GroupsApproved; Investigational
Direct ClassificationMethoxyanilines
SMILESCOC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
Pathways
PharmGKB
ChEMBLCHEMBL2103830